2/10
04:41 pm
lbrx
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
2/5
08:00 am
lbrx
LB Pharmaceuticals Announces $100.0 Million Private Placement
Medium
Report
LB Pharmaceuticals Announces $100.0 Million Private Placement
1/27
08:33 am
lbrx
LB Pharmaceuticals initiates Phase 2 trial of LB-102 [Yahoo! Finance]
Low
Report
LB Pharmaceuticals initiates Phase 2 trial of LB-102 [Yahoo! Finance]
1/26
08:00 am
lbrx
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
Medium
Report
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
1/21
08:00 am
lbrx
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
Low
Report
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
1/12
04:05 pm
lbrx
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
1/10
05:43 am
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Medium
Report
LB Pharmaceuticals (NASDAQ:LBRX) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
1/9
05:03 am
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
Low
Report
LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
1/6
07:22 am
lbrx
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture [Yahoo! Finance]
Low
Report
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture [Yahoo! Finance]
1/6
07:00 am
lbrx
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
Low
Report
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
12/17
04:35 pm
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
LB Pharmaceuticals (NASDAQ:LBRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
04:20 pm
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
LB Pharmaceuticals (NASDAQ:LBRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
08:44 am
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) had its price target raised by analysts at Stifel Nicolaus from $27.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
LB Pharmaceuticals (NASDAQ:LBRX) had its price target raised by analysts at Stifel Nicolaus from $27.00 to $35.00. They now have a "buy" rating on the stock.
12/10
06:01 pm
lbrx
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/10
05:04 pm
lbrx
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
12/9
07:04 pm
lbrx
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices [Yahoo! Finance]
Low
Report
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices [Yahoo! Finance]
12/9
08:00 am
lbrx
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
Low
Report
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
12/5
04:23 pm
lbrx
LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
High
Report
LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.